Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly US$ 21.95 Min. order: 1 piece ★★★★★ 4.5 (247 reviews) Sold : Login>>
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data US$ 25.70 Min. order: 1 piece ★★★★★ 4.5 (256 reviews) Sold : Login>>
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment US$ 22.44 Min. order: 1 piece ★★★★★ 4.5 (13 reviews) Sold : Login>>
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide US$ 22.60 Min. order: 1 piece ★★★★★ 4.9 (209 reviews) Sold : Login>>
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' – NBC Connecticut US$ 20.10 Min. order: 1 piece ★★★★★ 4.5 (195 reviews) Sold : Login>>